首页> 美国卫生研究院文献>Proteomes >Mass Spectrometric Studies of Apolipoprotein Proteoforms and Their Role in Lipid Metabolism and Type 2 Diabetes
【2h】

Mass Spectrometric Studies of Apolipoprotein Proteoforms and Their Role in Lipid Metabolism and Type 2 Diabetes

机译:载脂蛋白蛋白形式的质谱研究及其在脂质代谢和2型糖尿病中的作用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Apolipoproteins function as structural components of lipoprotein particles, cofactors for enzymes, and ligands for cell-surface receptors. Most of the apoliporoteins exhibit proteoforms, arising from single nucleotide polymorphisms (SNPs) and post-translational modifications such as glycosylation, oxidation, and sequence truncations. Reviewed here are recent studies correlating apolipoproteins proteoforms with the specific clinical measures of lipid metabolism and cardiometabolic risk. Targeted mass spectrometric immunoassays toward apolipoproteins A-I, A-II, and C-III were applied on large cross-sectional and longitudinal clinical cohorts. Several correlations were observed, including greater apolipoprotein A-I and A-II oxidation in patients with diabetes and cardiovascular disease, and a divergent apoC-III proteoforms association with plasma triglycerides, indicating significant differences in the metabolism of the individual apoC-III proteoforms. These are the first studies of their kind, correlating specific proteoforms with clinical measures in order to determine their utility as potential clinical biomarkers for disease diagnosis, risk stratification, and therapy decisions. Such studies provide the impetus for the further development and clinical translation of MS-based protein tests.
机译:载脂蛋白充当脂蛋白颗粒的结构成分,酶的辅因子和细胞表面受体的配体。大多数的载脂蛋白都表现出蛋白形式,这是由于单核苷酸多态性(SNP)和翻译后修饰(例如糖基化,氧化和序列截短)引起的。本文回顾了最近的研究,这些研究将载脂蛋白蛋白形式与脂代谢和心脏代谢风险的特定临床指标联系起来。针对载脂蛋白A-I,A-II和C-III的靶向质谱免疫分析已应用于大型横截面和纵向临床队列。观察到了几种相关性,包括糖尿病和心血管疾病患者中载脂蛋白A-I和A-II的氧化增加,以及与血浆甘油三酸酯相关的apoC-III蛋白形式的差异,表明各个apoC-III蛋白形式的代谢存在显着差异。这些是此类研究的首次,将特定的蛋白形式与临床指标相关联,以确定其作为疾病诊断,风险分层和治疗决策的潜在临床生物标记物的效用。这些研究为基于MS的蛋白质测试的进一步发展和临床翻译提供了动力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号